CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

UAE Crescent Enterprises’ CE-Ventures invests in London startup Oyster Therapeutics

By Zawya

By Staff Writer

UAE-based Crescent Enterprises’ CE-Ventures has invested in London-based biotech firm Oyster Therapeutics, formerly Kesmalea Therapeutics.

The venture capital platform participated in the UK company’s $60 million Series A-2 funding round to advance targeted protein degraders for neurodegenerative diseases such as Alzheimer’s.

The investment round was led by 4BIO Capital, a London-based specialist life science VC fund, with participation from Actium Group, Eli Lilly and Company and TOHO Ventures.

The funding round also drew participation from existing investors Syncona, Oxford Science Enterprises (OSE), Mission BioCapital and MGB Ventures.

(Writing by Cleofe Maceda. Editing by Seban Scaria)
(seban.scaria@lseg.com )

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.